Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 217

The DOI matches its Crossref record.

L-Asparaginase and PEG Asparaginase— Past, Present, and Future

Keating, Michael J., Holmes, Romayne, Lerner, Susan, Ho, Dah Hsi·1993·Leukemia & Lymphoma

Abstract

L-asparaginase is an enzyme which hydrolyses asparagine. Since the 1960s it has been known that some leukemic cells are deficient in asparagine synthetase and therefore cannot manufacture sufficient quantities of this essential amino acid to maintain cell viability. L-asparaginase is predominantly useful in acute lymphocytic leukemia (ALL) although responses have been noted in patients with acute myeloid leukemia, lymphoma, and rarely other tumors. L-asparaginase has been used in conjunction with methotrexate and ara-C in combination programs in leukemia. The major side-effect limiting the usefulness of L-asparaginase is allergic reactions. In addition, it is probable that neutralizing antibodies develop which shorten the half life of the drug so that the goal of depletion of plasma levels of asparagine cannot be attained or maintained. Polyethylene glycol (M.W. 5000) can be conjugated to L-asparaginase at sites not involving the active site of the enzyme. This enables free access of a small molecule, asparagine, to the active site of the enzyme but prevents uptake by the reticuloendothelial system, greatly decreasing the probability of developing antibodies against the asparaginase and prolongs the circulating half life of the drug. In a phase I/II study conducted at the M.D. Anderson Cancer Center, 37 heavily pretreated patients with refractory hematologic malignancy were treated. The age range from 15 to 73 years, median 49 years. Nineteen patients had ALL, 15 lymphoma, two myeloma, and one Hodgkin's disease. The dose levels of PEG L-asparaginase varied from 250 IU/m2 up to 8000 IU/m2. The pharmacokinetic profile demonstrated a mono-phasic half life consistent with a one compartment model with a single elimination phase. The mean t1/2 of PEG L-asparaginase was 357 hours compared with 20 hours for L-asparaginase. The major side effects were nausea and vomiting, peripheral edema, hypoalbuminemia and hepatic dysfunction. Three patients developed allergic reactions. There was no clear relationship between the dose of PEG L-asparaginase and toxicity. Three patients achieved complete remission, two with lymphoma, and one with ALL. Doses were repeated at two week intervals. Asparaginase depletion was documented to persist until the next dose. Thus PEG L-asparaginase allows for less frequent dosing, good tolerance, and persistent asparagine depletion with an acceptable toxicity profile. Further evaluation of the role of PEG L-asparaginase in patients who are documented to be hypersensitive to native L-asparaginase is indicated and additional clinical trials are being conducted to evaluate response.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3109/10428199309149129

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 217

Metadata

Authors
Keating, M. J., Holmes, R., Lerner, S., & Ho, D. H.
Venue
Leukemia & Lymphoma
Published
1993-01
Volume
10
Issue
sup1
Pages
153-157
ISSN
  • 1026-8022 (ISSN-L)
  • 1042-8194
  • 1029-2403
OpenAlex
W2156945455
Cited by
217
References
0
FWCI
3.03
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: L-Asparaginase and PEG Asparaginase— Past, Present, and Future. https://app.cochat.ai/papers/10.3109/10428199309149129
The paper
Keating, M. J., Holmes, R., Lerner, S., & Ho, D. H. (1993). L-Asparaginase and PEG Asparaginase— Past, Present, and Future. Leukemia & Lymphoma. https://doi.org/10.3109/10428199309149129

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.